SEARCH

SEARCH BY CITATION

References

  • 1
    Jares P,Colomer D,Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7: 75062.
  • 2
    Herreros B,Sanchez-Aguilera A,Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia 2008; 22: 4958.
  • 3
    Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005; 5: 25162.
  • 4
    de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23: 635863.
  • 5
    Wahlin BE,Sander B,Christensson B,Kimby E. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma. Clin Cancer Res 2007; 13: 38897.
  • 6
    Flygare J,Gustafsson K,Kimby E,Christensson B,Sander B. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. FEBS Lett 2005; 579: 68859.
  • 7
    Gustafsson K,Christensson B,Sander B,Flygare J. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55,212 is associated with ceramide accumulation and p38 activation in Mantle Cell Lymphoma. Mol Pharmacol 2006; 70: 161220.
  • 8
    Islam TC,Asplund AC,Lindvall JM,Nygren L,Liden J,Kimby E,Christensson B,Smith CI,Sander B. High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma. Leukemia 2003; 17: 188090.
  • 9
    Di Marzo V,Bifulco M,De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3: 77184.
  • 10
    Ryberg E,Vu HK,Larsson N,Groblewski T,Hjorth S,Elebring T,Sjogren S,Greasley PJ. Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 2005; 579: 25964.
  • 11
    Bouaboula M,Rinaldi M,Carayon P,Carillon C,Delpech B,Shire D,Le Fur G,Casellas P. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 1993; 214: 17380.
  • 12
    Galiegue S,Mary S,Marchand J,Dussossoy D,Carriere D,Carayon P,Bouaboula M,Shire D,Le Fur G,Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 5461.
  • 13
    Daaka Y,Friedman H,Klein TW. Cannabinoid receptor proteins are increased in Jurkat, human T-cell line after mitogen activation. J Pharmacol Exp Ther 1996; 276: 77683.
  • 14
    Noe SN,Newton C,Widen R,Friedman H,Klein TW. Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes. J Neuroimmunol 2000; 110: 1617.
  • 15
    Noe SN,Newton C,Widen R,Friedman H,Klein TW. Modulation of CB1 mRNA upon activation of murine splenocytes. Adv Exp Med Biol 2001; 493: 21521.
  • 16
    Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005; 5: 40011.
  • 17
    Ek S,Hogerkorp CM,Dictor M,Ehinger M,Borrebaeck CA. Mantle cell lymphomas express a distinct genetic signature affecting lymphocyte trafficking and growth regulation as compared with subpopulations of normal human B cells. Cancer Res 2002; 62: 4398405.
  • 18
    Flygare J,Sander B. The endocannabinoid system in cancer-Potential therapeutic target? Semin Cancer Biol; in press.
  • 19
    Bifulco M,Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002; 8: 54750.
  • 20
    Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003; 3: 74555.
  • 21
    Bifulco M,Laezza C,Pisanti S,Gazzero P. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 2006; 148: 12325.
  • 22
    Herrera B,Carracedo A,Diez-Zaera M,Guzman M,Velasco G. p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. FEBS Lett 2005; 579: 50848.
  • 23
    McKallip RJ,Lombard C,Fisher M,Martin BR,Ryu S,Grant S,Nagarkatti PS,Nagarkatti M. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 2007; 100: 62734.
  • 24
    Rayman N,Lam KH,Van Leeuwen J,Mulder AH,Budel LM,Lowenberg B,Sonneveld P,Delwel R. The expression of the peripheral cannabinoid receptor on cells of the immune system and non-Hodgkin's lymphomas. Leuk Lymphoma 2007; 48: 138999.
  • 25
    JaffeES,HarrisNL,SteinH,VardimanJW, eds. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
  • 26
    Rimokh R,Berger F,Bastard C,Klein B,French M,Archimbaud E,Rouault JP,Santa Lucia B,Duret L,Vuillaume M,Coiffier B,Bryon P-A,Magaud JP. Rearrangement of CCND1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and t(11q13)-associated leukemias. Blood 1994; 83: 368996.
  • 27
    Rundlof AK,Fernandes AP,Selenius M,Babic M,Shariatgorji M,Nilsonne G,Ilag LL,Dobra K,Bjornstedt M. Quantification of alternative mRNA species and identification of thioredoxin reductase 1 isoforms in human tumor cells. Differentiation 2007; 75: 12332.
  • 28
    Borner C,Hollt V,Sebald W,Kraus J. Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukoc Biol 2007; 81: 33643.
  • 29
    Bifulco M,Laezza C,Portella G,Vitale M,Orlando P,De Petrocellis L,Di Marzo V. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J 2001; 15: 27457.
  • 30
    Bifulco M,Laezza C,Valenti M,Ligresti A,Portella G,Di Marzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 2004; 18: 16068.
  • 31
    Blazquez C,Carracedo A,Barrado L,Real PJ,Fernandez-Luna JL,Velasco G,Malumbres M,Guzman M. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006; 20: 26335.
  • 32
    Blazquez C,Casanova ML,Planas A,Del Pulgar TG,Villanueva C,Fernandez-Acenero MJ,Aragones J,Huffman JW,Jorcano JL,Guzman M. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003; 17: 52931.
  • 33
    Casanova ML,Blazquez C,Martinez-Palacio J,Villanueva C,Fernandez-Acenero MJ,Huffman JW,Jorcano JL,Guzman M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 4350.
  • 34
    Guzman M,Duarte MJ,Blazquez C,Ravina J,Rosa MC,Galve-Roperh I,Sanchez C,Velasco G,Gonzalez-Feria L. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer 2006; 95: 197203.
  • 35
    Laezza C,Pisanti S,Crescenzi E,Bifulco M. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 2006; 580: 607682.
  • 36
    Ligresti A,Bisogno T,Matias I,De Petrocellis L,Cascio MG,Cosenza V,D'Argenio G,Scaglione G,Bifulco M,Sorrentini I,Di Marzo V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003; 125: 67787.
  • 37
    Ligresti A,Moriello AS,Starowicz K,Matias I,Pisanti S,De Petrocellis L,Laezza C,Portella G,Bifulco M,Di Marzo V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006; 318: 137587.
  • 38
    Melck D,De Petrocellis L,Orlando P,Bisogno T,Laezza C,Bifulco M,Di Marzo V. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000; 141: 11826.
  • 39
    Melck D,Rueda D,Galve-Roperh I,De Petrocellis L,Guzman M,Di Marzo V. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999; 463: 23540.
  • 40
    Portella G,Laezza C,Laccetti P,De Petrocellis L,Di Marzo V,Bifulco M. Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. FASEB J 2003; 17: 17713.
  • 41
    Sanchez C,de Ceballos ML,del Pulgar TG,Rueda D,Corbacho C,Velasco G,Galve-Roperh I,Huffman JW,Ramon y Cajal S,Guzman M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001; 61: 57849.
  • 42
    Sarfaraz S,Afaq F,Adhami VM,Malik A,Mukhtar H. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 2006; 281: 3948091.
  • 43
    Sarfaraz S,Afaq F,Adhami VM,Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 2005; 65: 163541.
  • 44
    Caffarel MM,Sarrio D,Palacios J,Guzman M,Sanchez C. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006; 66: 661521.
  • 45
    Ellert-Miklaszewska A,Grajkowska W,Gabrusiewicz K,Kaminska B,Konarska L. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res 2007; 1137: 1619.
  • 46
    Held-Feindt J,Dorner L,Sahan G,Mehdorn HM,Mentlein R. Cannabinoid receptors in human astroglial tumors. J Neurochem 2006; 98: 88693.
  • 47
    Carracedo A,Gironella M,Lorente M,Garcia S,Guzman M,Velasco G,Iovanna JL. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006; 66: 674855.
  • 48
    Maresz K,Pryce G,Ponomarev ED,Marsicano G,Croxford JL,Shriver LP,Ledent C,Cheng X,Carrier EJ,Mann MK,Giovannoni G,Pertwee RG, et al. Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007; 13: 4927.
  • 49
    Shire D,Carillon C,Kaghad M,Calandra B,Rinaldi-Carmona M,Le Fur G,Caput D,Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995; 270: 372631.
  • 50
    Do Y,McKallip RJ,Nagarkatti M,Nagarkatti PS. Activation through cannabinoid receptors 1 and 2 on dendritic cells triggers NF-kappaB-dependent apoptosis: novel role for endogenous and exogenous cannabinoids in immunoregulation. J Immunol 2004; 173: 237382.
  • 51
    De Petrocellis L,Melck D,Palmisano A,Bisogno T,Laezza C,Bifulco M,Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci USA 1998; 95: 837580.